AIM Vaccine submits additional NMPA data for serum-free rabies vaccine after Phase III trial unblinding

• AIM Vaccine completed submission of supplementary data to China’s NMPA for market registration of its serum-free iterative rabies vaccine.
• Phase III results were already presented internally following unblinding, showing favorable safety and immune response that met trial criteria.
• The filing keeps the product on track for potential approval, supporting a rapid commercial launch using existing large-scale manufacturing capacity.
• The program targets China’s rabies vaccine market, projected to reach RMB 14.8 billion by 2030, with clinics required to stock at least two vaccine types.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. AIM Vaccine Co. Ltd. published the original content used to generate this news brief via IIS, the regulatory disclosure system operated by the Hong Kong Stock Exchange (HKex) (Ref. ID: HKEX-EPS-20260803-12265598), on August 03, 2026, and is solely responsible for the information contained therein.